Latigo reports Q3 2026 results, names new CEO, adds opioid arm to Phase 3 trialNov 5Quarterly updateCollegium Pharmaceutical, IncLatigo Biotherapeutics
Merck registers Phase 2b trial of tulisokibart for noninfectious uveitisOct 9Weekly roundup, 8 itemsglycopyrrolateMerck & Co., Inc.
Viatris registers Phase 4 abuse-potential trial of gabapentin plus oxycodoneSep 10Trial updategabapentinoxycodone